S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

RDHL Redhill Biopharma Ltd

0.3657

-0.0043 (-1.16%)

Jun 21 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Redhill Biopharma Charts.

Redhill Biopharma (NASDAQ:RDHL)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Redhill Biopharma Charts.

Redhill Biopharma Ltd News

Form S-8 - Securities to be offered to employees in employee benefit plans
Thursday 20 June 2024 (3 days ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 6 June 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 3 June 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 6 May 2024 (2 months ago) • Edgar (US Regulatory)

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
Monday 6 May 2024 (2 months ago) • PR Newswire (US)

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Wednesday 24 April 2024 (2 months ago) • PR Newswire (US)

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Monday 8 April 2024 (3 months ago) • PR Newswire (US)

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Tuesday 2 April 2024 (3 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 11 March 2024 (3 months ago) • Edgar (US Regulatory)

RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Monday 11 March 2024 (3 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 5 March 2024 (4 months ago) • Edgar (US Regulatory)

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Tuesday 5 March 2024 (4 months ago) • PR Newswire (US)

More Redhill Biopharma Ltd News Articles

Torontodominion Bank Iss...

International Bank for R...

Invesco Next Gen Connect...

Offerpad Solutions

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions